Cost-effectiveness of trabectedin plus pegylated liposomal doxorubicin for the treatment of women with relapsed platinum-sensitive ovarian cancer in the UK: Analysis based on the final survival data of the OVA-301 trial

Value in Health

Volumn 16, Issue 4, 2013, Pages 507-516

  Fisher, Mark ^a   Gore, Martin ^b  

^a WG Consulting   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

cost effectiveness analysis; decision analytic model; ovarian cancer; trabectedin; UK

Indexed keywords

CA 125 ANTIGEN; DOXORUBICIN; PLATINUM; TRABECTEDIN;

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; HUMAN; LIFESPAN; MONOTHERAPY; NATIONAL HEALTH SERVICE; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RETREATMENT; SOCIAL WORK; UNITED KINGDOM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DIOXOLES; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; GREAT BRITAIN; HUMANS; MODELS, THEORETICAL; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL ANALYSIS; SURVIVAL RATE; TETRAHYDROISOQUINOLINES;

EID: 84879417789     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2013.01.011     Document Type: Article

References (31)

1. R.F. Ozols Treatment goals in ovarian cancer Int J Gynecol Cancer 15 Suppl. 1 2005 3 11
2. B.J. Monk, and R.L. Coleman Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds Int J Gynecol Cancer 19 Suppl. 2 2009 S63 S67
3. M.E. Gore, I. Fryatt, E. Wiltshaw, and T. Dawson Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds J Gynecol Oncol 36 1990 207 211
4. M. Markman, A.N. Gordon, and W.P. McGuire Liposomal anthracycline treatment for ovarian cancer Semin Oncol 31 6, Suppl. 13 2004 91 105
5. M. Markman, R. Rothman, and T. Hakes Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin J Clin Oncol 9 1991 389 393
6. G. Ferrandina, M. Ludovisi, and D. Lorusso Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer J Clin Oncol 26 2008 890 896
7. A.N. Gordon, J.T. Fleagle, and D. Guthrie Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 2001 3312 3332
8. National Institute for Health and Clinical Excellence. Technology Appraisal 91. Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer. Updated May 2005. Available from: http://guidance.nice.org.uk/nicemedia/live/ 11554/33024/33024.pdf. [Accessed January 31, 2013].
9. B.J. Monk, T.J. Herzog, and S.B. Kaye Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 2010 3107 3114
10. B.J. Monk, T.J. Herzog, and S.B. Kaye Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis Eur J Cancer 48 2012 2361 2368
11. European Medicines Agency. Assessment report for Yondelis. October 28, 2009. Available from: http://www.emea.europa.eu/docs/en-GB/document-library/ EPAR-Assessment-Report-Variation/human/000773/WC500059175.pdf. [Accessed January 31, 2012].
12. National Institute for Health and Clinical Excellence. Technology Appraisal Guidance 222. Trabectedin for the treatment of relapsed ovarian cancer. Updated April 2011. Available from: http://guidance.nice.org.uk/ nicemedia/live/13466/54212/54212.pdf. [Accessed January 31, 2012].
13. Main C, Ginnelly L, Griffin S, et al. Centre for Review and Dissemination (CRD), University of York. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer (report contains no commercial in confidence data). September 2004. Available from: http://www.nice.org.uk/nicemedia/live/11553/33023/33023. pdf. [Accessed January 31, 2012].
14. School of Health and Related Research. Trabectedin for the treatment of relapsed ovarian cancer: a single technology appraisal. April 2010. Available from: http://www.hta.ac.uk/erg/reports/2215.pdf. [Accessed January 31, 2013].
15. G.J. Rustin, R.C.J. Bast, and G.J. Kelloff Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer Clin Cancer Res 10 2004 3919 3926
16. G.J. Rustin, A.E. Nelstrop, and P. McClean Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125 J Clin Oncol 14 1996 1545 1551
17. T.J. Herzog, J.B. Vermorken, and E. Pujade-Lauraine Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study Gynecol Oncol 122 2011 350 355
18. Joint Formulary Committee. British National Formulary (Vol. 62). BMJ Group and Pharmaceutical Press, 2011. Available from: http://bnf.org/bnf/. [Accessed January 31, 2013].
19. Department of Health. National Health Service reference costs 10/11. Available from: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-131140. [Accessed January 31, 2013].
20. J.F. Guest, F.J. Ruiz, and M.J. Greener Palliative care treatment patterns and associated costs of healthcare resource use for specific advanced cancer patients in the UK Eur J Cancer Care (Engl) 15 2006 65 73
21. Curtis L. Unit costs of health and social care. 2011. Available from: http://www.pssru.ac.uk/. [Accessed January 31, 2013].
22. National Institute for Health and Clinical Excellence. Appraising life-extending, end of life treatments. Updated January 2009. Available from: http://www.nice.org.uk/media/88A/F2/SupplementaryAdviceTACEoL.pdf. [Accessed January 31, 2013.
23. National Institute for Health and Clinical Excellence. Technology Appraisal Guidance 169. Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma. Issue date 2009. Available from: http://www.nice.org.uk/nicemedia/live/12143/43556/43556.pdf. [Accessed January 31, 2013].
24. J. Sehouli, V. Alfaro, and A. Gonzalez-Martin Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives Ann Oncol 23 3 2012 556 562
25. U.A. Matulonis, N.S. Horowitz, and S.M. Campos Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer J Clin Oncol 26 35 2008 5761 5766
26. F. Joly, I. Ray-Coquard, and M. Fabbro Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial Gynecol Oncol 122 2 2011 226 232
27. A. Polyzos, N. Tsavaris, and C. Kosmas Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience Oncology 61 2001 129 133
28. M.J. Kandel, A. Loehr, and P. Harter Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatin hypersensitivity Int J Gynecol Cancer 15 2005 780 784
29. J.R. Schwartz, C. Bandera, and A. Bradley Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital Gynecol Oncol 105 2007 81 83
30. S. Pignata, S. De Placido, and R. Biamonte Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study BMC Cancer 6 2006 5 11
31. National Institute of Health and Clinical Excellence. Guide to the methods of technology appraisal. Issue date 2008. Available from: http://www.nice.org.uk/media/b52/a7/tamethodsguideupdatedjune2008.pdf. [Accessed January 31, 2013].